Which angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB) has the greatest antihypertensive effect?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Which ACE Inhibitor or ARB Has the Greatest Antihypertensive Effect?

No single ACE inhibitor or ARB demonstrates superior antihypertensive efficacy over others within their respective classes—all agents lower blood pressure similarly when dosed appropriately, though ACE inhibitors may provide slightly better cardiovascular outcomes than ARBs. 1

Blood Pressure Lowering: Class Effect

The evidence consistently shows that antihypertensive efficacy is a class effect rather than agent-specific:

  • Within-class equivalence: All ACE inhibitors (captopril, enalapril, lisinopril, ramipril, perindopril, quinapril, fosinopril, trandolapril) and all ARBs (losartan, valsartan, candesartan, irbesartan, telmisartan, olmesartan, eprosartan) produce comparable blood pressure reductions when titrated to maximum approved doses 2, 3

  • Between-class comparison: ACE inhibitors and ARBs lower blood pressure to similar degrees. A 2024 systematic review of 1.6 million patients confirmed equivalent blood pressure lowering capacity between these two classes 1

  • Dosing matters more than agent selection: The key is titrating to the highest tolerated dose within the approved range, as higher doses provide greater blood pressure reduction 2, 4

Cardiovascular Outcomes: ACE Inhibitors Show Slight Advantage

While blood pressure lowering is equivalent, ACE inhibitors demonstrate superior reduction in cardiovascular events and all-cause mortality compared to ARBs 1. This finding from a 2024 systematic review analyzing over 1.6 million patients represents the most recent high-quality evidence on this question.

In head-to-head trials:

  • The ONTARGET study (2009) compared ramipril 10 mg versus telmisartan 80 mg in 25,620 high-risk patients and found no significant difference in cardiovascular death, MI, stroke, or heart failure hospitalization between the two agents 5
  • However, the broader evidence base favors ACE inhibitors for hard outcomes 1

Practical Selection Algorithm

Start with an ACE inhibitor unless contraindicated:

  1. First choice: ACE inhibitor (any agent from the table below)

    • Better cardiovascular outcomes 1
    • Lower cost
    • Proven mortality benefit across multiple trials

  2. Switch to ARB if:

    • Intolerable cough develops (most common reason)
    • Angioedema occurs (absolute contraindication to ACE inhibitors)
    • Patient preference for better tolerability 1

  3. Titrate to maximum approved dose before adding second agent 2, 4

Dosing Ranges for Common Agents

ACE Inhibitors 2, 3:

  • Ramipril: 1.25-20 mg daily (target 10 mg)
  • Lisinopril: 2.5-40 mg daily (target 20-40 mg)
  • Enalapril: 2.5-20 mg twice daily (target 10-20 mg twice daily)
  • Perindopril: 2-16 mg daily (target 8-16 mg)

ARBs 2, 3:

  • Candesartan: 2-32 mg daily (target 32 mg)
  • Valsartan: 80-320 mg daily (target 160 mg twice daily)
  • Telmisartan: 40-80 mg daily (target 80 mg)
  • Losartan: 25-100 mg daily (target 50-100 mg)

Special Populations

Black patients: Thiazide diuretics or calcium channel blockers are more effective than ACE inhibitors or ARBs as monotherapy and should be first-line 6, 7. However, ACE inhibitors/ARBs remain appropriate as add-on therapy or in patients with CKD and proteinuria.

Diabetic kidney disease with albuminuria: Both ACE inhibitors and ARBs are equally effective at slowing progression 2, 4. Choose based on tolerability.

Heart failure with reduced ejection fraction: ACE inhibitors are preferred first-line; ARBs are equivalent alternatives if ACE inhibitors are not tolerated 3, 8

Critical Caveat: Avoid Dual RAS Blockade

Do not combine ACE inhibitors with ARBs—this increases adverse events (hypotension, hyperkalemia, renal impairment) without additional cardiovascular benefit 5, 9. The ONTARGET trial definitively showed combination therapy increased dialysis risk (HR 1.09) and discontinuation rates without improving outcomes 5.

Bottom Line

Choose any ACE inhibitor as first-line therapy and titrate to maximum approved dose. If not tolerated, switch to any ARB at maximum dose. The specific agent matters far less than achieving adequate dosing and blood pressure control. ACE inhibitors have a slight edge in cardiovascular outcomes, but ARBs are reasonable alternatives with better tolerability.

References

Related Questions

What is the most commonly used angiotensin‑converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)?
Are angiotensin II receptor blockers (ARBs) better than ACE inhibitors, equivalent to ACE inhibitors, have an additive effect with ACE inhibitors, or have the same adverse effect potential as ACE inhibitors?
Which angiotensin‑converting enzyme inhibitors (ACE inhibitors) or angiotensin II receptor blockers (ARBs) are most effective for reducing proteinuria?
In atrial fibrillation, should a calcium‑channel blocker or an ACE inhibitor/angiotensin‑receptor blocker be used as first‑line therapy?
Is amiodarone an ACE inhibitor or an ARB (angiotensin receptor blocker)?
What are the clinical criteria for common ENT conditions such as acute bacterial sinusitis, acute otitis media, streptococcal pharyngitis, and Meniere disease?
Why is nifedipine preferred over nicardipine for acute blood pressure control in severe preeclampsia?
Is immunotherapy indicated for a patient with a completely resected ciliary body melanoma who now has a locally recurrent tumor with clear surgical margins?
What are the possible causes of unintentional weight loss despite high caloric intake?
What is the appropriate management for a patient with atelectasis and elevated C-reactive protein (CRP)?
For treating hyperkalaemia, should I use Lokelma (sodium zirconium cyclosilicate) sachet instead of other potassium binders such as sodium polystyrene sulfonate or patiromer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.